Description: In this presentation, common and/or challenging issues arising from the use of BTK inhibitors will be discussed, using an engaging case-based format. Cases will be relevant to the Canadian landscape and provide the learner with practical tips on optimizing use of BTK inhibitors.

Speaker: Christine Chen, MD MEd FRCPC
Princess Margaret Cancer Centre
Associate Professor
Division of Medical Oncology and
Hematology Department of Medicine
Temerty Faculty of Medicine
University of Toronto

Learning Objectives:
1. Review the differences and rationale for use of available BTK inhibitors in Canada.

2. Discuss the impact of dose modifications, interruptions and early cessation of BTK inhibitors.

3 Identify how to minimize and manage BTK toxicity.

Accreditation: This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists (CAP-AC). You may claim a maximum of 1.0 hours. Certificates of Attendance will be sent to all CHS members who participate.

This webinar is supported by a grant from BEIGENE and the CHS Scientific Planning Committee has planned it to achieve scientific integrity, objectivity and balance.

Target Audience: Hematologists, Medical Oncologists, Residents, Pharmacists

Conflicts of Interest: Honoraria for advisory board participant, and speaker honorarium – Janssen, Astrazeneca, Beigene, Forus
Research funding: Janssen